Exciting Developments at Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, a prominent clinical-stage pharmaceutical company, has recently announced new equity awards, demonstrating its commitment to fostering talent and innovation. The announcement, made on August 10, 2025, involved the granting of non-qualified stock option awards and restricted stock unit (RSU) awards to a select group of new non-executive employees.
Overview of the Stock Awards
In total, Crinetics has issued options to purchase 75,850 shares of common stock and RSUs amounting to 53,400 shares. These awards were granted under the 2021 Employment Inducement Incentive Award Plan, designed specifically for individuals entering employment with the company. By adhering to Nasdaq Listing Rule 5635(c)(4), Crinetics emphasizes the strategic role of these inducements in attracting new talent.
Details on Stock Options and RSUs
Each stock option comes with an exercise price set at $26.85, matching the closing price of Crinetics’ common stock on the Nasdaq Global Select Market. The structure of the vesting illustrates the company’s prudent approach: 25% of the stock options will vest on the one-year anniversary, with the remainder vesting over the following three years through monthly installments. Similarly, the awarded RSUs will vest equally over four years, starting one year post-grant, contingent upon continued employment.
About Crinetics Pharmaceuticals
At the forefront of pharmaceuticals, Crinetics focuses on innovative treatments for endocrine diseases and related tumors. Notably, their lead candidate, PALSONIFY (paltusotine), is a groundbreaking oral medication designed specifically for treating acromegaly. This candidate represents a significant advancement, being the first of its kind in clinical testing for this condition.
Further Research and Development
Beyond PALSONIFY, Crinetics is also developing Atumelnant for congenital adrenal hyperplasia and other conditions, reinforcing its strategic focus on diverse endocrine disorders. Their commitment to research has yielded a portfolio of pioneering small molecule therapies aimed to transform the treatment landscape for various endocrine issues, such as hyperparathyroidism and Graves’ disease.
Crinetics Pharmaceuticals’ Vision
The investments in employee stock options and RSUs not only incentivize talent but align employee interests with the company's growth ambitions. This employee-centric approach showcases Crinetics' determination to build a robust and effective workforce that can lead the charge in developing transformative therapies.
Contact Information
For those interested in learning more about Crinetics Pharmaceuticals, the company has provided avenues for direct communication with their Investor Relations and Corporate Communications teams. Gayathri Diwakar leads the Investor Relations, and inquiries can be directed to her at gdiwakar@crinetics.com or via phone at (858) 345-6340. For media relations, Natalie Badillo can be contacted at nbadillo@crinetics.com, or (858) 450-6464.
Frequently Asked Questions
What are the stock options granted by Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals has granted stock option awards for 75,850 shares and RSUs for 53,400 shares to new employees.
How does the vesting structure of the stock options work?
The stock options vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly thereafter.
What is the primary focus of Crinetics Pharmaceuticals?
Crinetics is focused on discovering and developing novel therapies for endocrine diseases and associated tumors.
Who can I contact for more information about Crinetics?
You can reach out to Gayathri Diwakar for investor relations or Natalie Badillo for media inquiries through their respective email addresses.
What is PALSONIFY?
PALSONIFY (paltusotine) is Crinetics' lead candidate, aimed at treating acromegaly and is currently in clinical development.
